New hope for fanconi anemia: safer stem cell transplant trial opens
NCT ID NCT02143830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a stem cell transplant approach for people with Fanconi Anemia who don't have a perfectly matched donor. The goal is to see if using lower doses of chemotherapy before the transplant can reduce serious side effects. About 70 participants will receive a transplant from a partially matched or unrelated donor after a special drug regimen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109, United States
-
Memorial Sloan Kettering Cancer Center
COMPLETEDNew York, New York, 10174, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a single drink reveal how alcohol triggers oral cancer?
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- Half-Matched stem cell transplant offers hope for children with blood disorders
- Gene therapy aims to fix bone marrow failure in fanconi anemia
- New transplant method aims to reduce complications in bone marrow failure patients